Review : side effects of approved molecular targeted therapies in solid cancers
Major advances have been achieved in the field of biologically based therapies for cancer in the last few years, and some of the recently approved molecular-targeted therapies are now being used in daily clinical practice. These molecular targets are also expressed in normal cells, which explains the different grades of toxicity, resulting from the disruption of normal cellular function. In general, targeted molecular therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities. In this article, we review the toxicity and safety of various small molecules and monoclonal antibodies used in solid tumors, with discussion of the pathophysiology, correlation with response, and strategies for prevention and management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2007 |
|---|---|
| Erschienen: |
2007 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
The oncologist - 12(2007), 12 vom: 15. Dez., Seite 1443-55 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Widakowich, Christian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiogenesis Inhibitors |
|---|
| Anmerkungen: |
Date Completed 28.02.2008 Date Revised 19.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1634/theoncologist.12-12-1443 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM176587616 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM176587616 | ||
| 003 | DE-627 | ||
| 005 | 20231223144353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2007 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1634/theoncologist.12-12-1443 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0589.xml |
| 035 | |a (DE-627)NLM176587616 | ||
| 035 | |a (NLM)18165622 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Widakowich, Christian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Review |b side effects of approved molecular targeted therapies in solid cancers |
| 264 | 1 | |c 2007 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2008 | ||
| 500 | |a Date Revised 19.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Major advances have been achieved in the field of biologically based therapies for cancer in the last few years, and some of the recently approved molecular-targeted therapies are now being used in daily clinical practice. These molecular targets are also expressed in normal cells, which explains the different grades of toxicity, resulting from the disruption of normal cellular function. In general, targeted molecular therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities. In this article, we review the toxicity and safety of various small molecules and monoclonal antibodies used in solid tumors, with discussion of the pathophysiology, correlation with response, and strategies for prevention and management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a de Castro, Gilberto |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a de Azambuja, Evandro |e verfasserin |4 aut | |
| 700 | 1 | |a Dinh, Phuong |e verfasserin |4 aut | |
| 700 | 1 | |a Awada, Ahmad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The oncologist |d 1998 |g 12(2007), 12 vom: 15. Dez., Seite 1443-55 |w (DE-627)NLM095483306 |x 1549-490X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2007 |g number:12 |g day:15 |g month:12 |g pages:1443-55 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1634/theoncologist.12-12-1443 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2007 |e 12 |b 15 |c 12 |h 1443-55 | ||